Skip to main content
Toggle navigation
Drupal
Main navigation EN
About Crossject
Who we are
Governance
Partners
Our news
R&D
ZENEO® products
ZENEO®: needle-free technology
Pipeline
ZENEO® Sumatriptan
ZENEO® Adrenaline
ZENEO® Hydrocortisone
ZENEO® Midazolam
ZENEO® Naloxone
ZENEO® Methotrexate
ZENEO® Apomorphine
ZENEO® Terbutaline
Finances
Profile
Analyst coverage
Financial releases
Main navigation 2 EN
Press resources
Press releases
Image bank
Careers
Working at Crossject
Our careers
Available position and applications
Contact
FR
EN
Home
Finances
Financial releases
Financial releases
Release date
And
Year
All
2019
2018
2017
2016
2015
2014
2013
Apply
2019/10/14
Crossject signs a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Defense (DOD)
Read the release
2019/10/11
First-half 2019 results and business update
Read the release
2019/10/11
business up date : Focus on progress during last summer
Read the release
2019/06/18
Commercial agreement with DESITIN Pharma for ZENEO® Midazolam in Germany
Read the release
2019/04/18
End of the conversion of convertible bonds issued in 2018
Read the release
2019/03/15
Crossject - Slideshow Annual results 2018
Read the release
2019/03/13
Financial results 2018
Read the release
2019/03/01
Crossject : €1.1 million in funding granted jointly by Bpifrance and the Bourgogne Franche-Comté region
Read the release
2019/03/01
CROSSJECT- Gain of pharmaceutical establishment status
Read the release
2019/02/28
SUCCESS OF THE €4 MILLION CAPITAL INCREASE
Read the release
Pagination
Current page
1
Page
2
Page
3
Page
4
Next page
Next ›
Last page
Last »
